Market capitalization | $4.94b |
Enterprise Value | $12.89b |
P/E (TTM) P/E ratio | 4.93 |
EV/FCF (TTM) EV/FCF | 15.09 |
EV/Sales (TTM) EV/Sales | 2.03 |
P/S ratio (TTM) P/S ratio | 0.78 |
P/B ratio (TTM) P/B ratio | 34.28 |
Dividend yield | 5.84% |
Last dividend (FY23) | $1.12 |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
10 Analysts have issued a Organon & Co. forecast:
10 Analysts have issued a Organon & Co. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 6,346 6,346 |
3%
3%
|
|
Gross Profit | 3,718 3,718 |
3%
3%
|
|
EBITDA | 1,596 1,596 |
9%
9%
|
EBIT (Operating Income) EBIT | 1,344 1,344 |
13%
13%
|
Net Profit | 1,000 1,000 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.
Head office | United States |
CEO | Kevin Ali |
Employees | 10,000 |
Founded | 2020 |
Website | www.organon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.